Figure 7From: Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled studyImmunological markers (FAS P1 , FAS P2 ). Serum specific-IgG4 levels (A) and serum specific-IgE levels (B) at baseline, at the end of pollen period (Period 1), 4 months before the pollen period (Period 2) and at the end of the pollen period (Period 2).Back to article page